Results 41 to 50 of about 31,000 (231)

Idiopathic thrombocytopenic purpura

Japanese Journal of Thrombosis and Hemostasis, 2008
Point（1）診断は血小板減少をきたす他の疾患の除外を基本とする．（2）血小板数と出血症状の程度，背景因子やライフスタイルに基づいて治療適応を決める．（3）治療はまずステロイド療法,次いで摘脾を行う．（4）ITPと診断されればまずH. pyloriを検索し，陽性であれば除菌療法を優先する．
openaire   +3 more sources

Clinical surveillance of thrombotic microangiopathies in Scotland, 2003-2005

, 2008
The prevalence, incidence and outcomes of haemolytic uraemic syndrome (HUS) and thrombotic thrombocytopaenic purpura (TTP) are not well established in adults or children from prospective studies. We sought to identify both outcomes and current management
Todd, W.T.A., Beattie, T.J., Pollock, K.G.J., Young, D.   +3 more
core   +1 more source

Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience

Haematologica, 2012
Background Acquired thrombotic thrombocytopenic purpura is still associated with a 10–20% death rate. It has still not been possible to clearly identify early prognostic factors of death.
Ygal Benhamou, Cyrielle Assié, Pierre-Yves Boelle, Marc Buffet, Rana Grillberger, Sandrine Malot, Alain Wynckel, Claire Presne, Gabriel Choukroun, Pascale Poullin, François Provôt, Didier Gruson, Mohamed Hamidou, Dominique Bordessoule, Jacques Pourrat, Jean-Paul Mira, Véronique Le Guern, Claire Pouteil-Noble, Cédric Daubin, Philippe Vanhille, Eric Rondeau, Jean-Bernard Palcoux, Christiane Mousson, Cécile Vigneau, Guy Bonmarchand, Bertrand Guidet, Lionel Galicier, Elie Azoulay, Hanspeter Rottensteiner, Agnès Veyradier, Paul Coppo   +30 more
doaj   +1 more source

Treatment‐Related Adverse Events and Health‐Related Quality of Life Associated With Immune Checkpoint Inhibitor Treatment for Mucosal Head and Neck Squamous Cell Carcinoma: A Scoping Review

Head &Neck, EarlyView.
ABSTRACT Background Supportive care needs of patients receiving immune checkpoint inhibitors (ICIs) for head and neck squamous cell carcinoma (HNSCC) are ill‐defined. Hence, known treatment‐related adverse events (TRAEs) and health‐related quality of life (HRQoL) associated with ICI treatment for HNSCC were examined to inform future supportive care ...
N. D. O'Donnell, E. C. Ward, L. R. Wishart, R. Perera, C. Barrett, K. A. Edmiston, E. Mitchell, A. Pigott, R. Pitt, K. Russell, B. A. Chan, R. Ladwa   +11 more
wiley   +1 more source

Current management of thrombotic thrombocytopenic purpura

, 2008
PURPOSE OF REVIEW: New treatment modalities have become increasingly popular for the treatment of acute thrombotic thrombocytopenic purpura. Widespread availability of ADAMTS13 assays resulted in the increased recognition of patients with hereditary ...
Kremer Hovinga, Johanna A, Meyer, Sara C
core   +1 more source

Perinatal outcomes in normotensive versus hypertensive HELLP syndrome

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract Objective To compare maternal and neonatal outcomes between women with hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome with and without associated hypertension. Methods This was a retrospective cohort study at a tertiary university‐affiliated medical center including all singleton HELLP cases >24 weeks gestation (January ...
Matan Anteby, Keren‐Or Wertheimer, Omri Dominsky, Liran Hiersch, Yariv Yogev   +4 more
wiley   +1 more source

Evaluating the efficacy of obturator cryoneurolysis for hip adductor spasticity: An observational, prospective study

PM&R, EarlyView.
Abstract Background Hip adductor spasticity is a common affliction among patients with disorders of the central nervous system. Cryoneurolysis is a novel intervention for spasticity involving the application of extreme cold to a nerve. This induces axonal breakdown, relieving spasticity.
Fraser MacRae, Mahdis Hashemi, Paul Winston   +2 more
wiley   +1 more source

Tuberculosis associated thrombocytopenic purpura: effectiveness of antituberculous therapy

Hematology Reports, 2009
Association of immune thrombocytopenic purpura and tuberculosis is a rare condition. In 5 patients presenting with this association, anti-tuberculous therapy was effective on both tuberculosis and thrombocytopenia suggesting a causal relationship between
Raphael Borie, Claire Fieschi, Eric Oksenhendler, Lionel Galicier   +3 more
doaj   +1 more source

Nanobodies as next‐generation targeting platforms: From discovery technologies to translational biomedicine

VIEW, EarlyView.
Nanobodies, derived from the variable domains of camelid heavy‐chain‐only antibodies, have emerged as transformative biomedical tools due to their nanoscale size, exceptional stability, and unique capacity to recognize cryptic epitopes. This review provides a comprehensive overview of the field, outlining the structural and biochemical features of ...
Zhenrui Ye, Xianyang Li, Meixiao Zhan
wiley   +1 more source

Immune Thrombocytopenic Purpura and Gastritis by H. pylori Associated With Type 1 Diabetes Mellitus

, 2016
We present the 15th case reported worldwide and 3rd case reported in Latin America of immune thrombocytopenic purpura associated with Type 1 diabetes mellitus in Scopus, MEDLINE, and SciELO.
Correa, Ricardo, Espinoza Morales, Frank, Mejia, Christian R., Flores-Guevara, Igor, Culquichicon-Sanchez, Carlos   +4 more
core   +1 more source